eli lilly tirzepatide shortage FDA to reconsider removal of weight loss drug from list Mounjaro will remain off shortage

Summary and future considerations Despite delivering significant weightloss and health benefits, GLP1 medications also present important limitations, including gastrointestinal side effects, nutrient shortfalls from the diet, loss of muscle mass, high costs, frequent discontinuation, and weight regain once treatment stops

Patients must clearly understand whether they are receiving a brand-name FDA-approved medication or a compounded alternative

Eligibility typically requires a body mass index (BMI) of 35 kg/m or above, or 30 kg/m with weight-related complications, and treatment is usually limited to 2 years

Additionally, monitoring for signs of biliary complications remains prudent

Results from the TRIUMPH-1 and TRANSCEND-T2D-1 trials were presented at the 86th Scientific Sessions of the American Diabetes Association (ADA)

These findings suggest that a high-salt diet may have context-dependent effects on different disease states